These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 16389641)

  • 1. Multi-method approach to valuing health states: problems with meaning.
    Nord E; Menzel P; Richardson J
    Health Econ; 2006 Feb; 15(2):215-8. PubMed ID: 16389641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of health states with rank-based nonmetric multidimensional scaling.
    Krabbe PF; Salomon JA; Murray CJ
    Med Decis Making; 2007; 27(4):395-405. PubMed ID: 17761959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-method approach to measuring health-state valuations.
    Salomon JA; Murray CJ
    Health Econ; 2004 Mar; 13(3):281-90. PubMed ID: 14981652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference-based index measurement of health-related quality of life: when does it reflect only arbitrary settings of the researcher?
    Konerding U
    Health Econ; 2011 Apr; 20(4):471-83. PubMed ID: 21394817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A theoretical framework for TTO valuations of health.
    Buckingham K; Devlin N
    Health Econ; 2006 Oct; 15(10):1149-54. PubMed ID: 16786547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do individuals consider expected income when valuing health states?
    Davidson T; Levin LA
    Int J Technol Assess Health Care; 2008; 24(4):488-94. PubMed ID: 18828945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling HUI 2 health state preference data using a nonparametric Bayesian method.
    Kharroubi SA; McCabe C
    Med Decis Making; 2008; 28(6):875-87. PubMed ID: 18971313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of an economic model of health states worse than dead.
    Sharma R; Stano M
    J Health Econ; 2010 Jul; 29(4):536-40. PubMed ID: 20633775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A note on the nature of utility in time and health and implications for cost utility analysis.
    Buckingham KJ; Devlin NJ
    Soc Sci Med; 2009 Jan; 68(2):362-7. PubMed ID: 19019518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parametric estimation of quality adjusted lifetime (QAL) distribution in progressive illness--death model.
    Pradhan B; Dewanji A
    Stat Med; 2009 Jul; 28(15):2012-27. PubMed ID: 19226565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuing health properly.
    Hausman DM
    Health Econ Policy Law; 2008 Jan; 3(Pt 1):79-83. PubMed ID: 18634634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assessment of health related quality of life--part 3--preference based measures].
    Horowitz E; Hassidim H; Abadi-Korek I; Shemer J
    Harefuah; 2008 Nov; 147(11):914-9, 938. PubMed ID: 19264015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of subjective life expectancy on health state valuations using a 10 year TTO.
    van Nooten FE; Koolman X; Brouwer WB
    Health Econ; 2009 May; 18(5):549-58. PubMed ID: 18702082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocols for time tradeoff valuations of health states worse than dead: a literature review.
    Tilling C; Devlin N; Tsuchiya A; Buckingham K
    Med Decis Making; 2010; 30(5):610-9. PubMed ID: 20068144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QALYs and the capability approach.
    Cookson R
    Health Econ; 2005 Aug; 14(8):817-29. PubMed ID: 15693028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inconsistencies in TTO and VAS values for EQ-5D health states.
    Lamers LM; Stalmeier PF; Krabbe PF; Busschbach JJ
    Med Decis Making; 2006; 26(2):173-81. PubMed ID: 16525171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the social value of health changes.
    Gyrd-Hansen D
    J Health Econ; 2004 Nov; 23(6):1101-16. PubMed ID: 15556238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthy year equivalents versus quality-adjusted life years: the debate continues.
    Towers I; Spencer A; Brazier J
    Expert Rev Pharmacoecon Outcomes Res; 2005 Jun; 5(3):245-54. PubMed ID: 19807594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life utilities for pelvic inflammatory disease health states.
    Smith KJ; Tsevat J; Ness RB; Wiesenfeld HC; Roberts MS
    Sex Transm Dis; 2008 Mar; 35(3):307-11. PubMed ID: 18032995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls?
    Korfage IJ; de Koning HJ; Habbema JD; Schröder FH; Essink-Bot ML
    BJU Int; 2007 Apr; 99(4):801-6. PubMed ID: 17233804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.